HC Wainwright Has Weak Outlook for Cytosorbents Q1 Earnings

Cytosorbents Corporation (NASDAQ:CTSO) – Equities researchers at HC Wainwright cut their Q1 2027 earnings per share (EPS) estimates for Cytosorbents in a report issued on Friday, August 7th. HC Wainwright analyst S. Lee now forecasts that the medical research company will post earnings of $0.00 per share for the quarter, down from their prior forecast of $0.01. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for Cytosorbents’ Q2 2027 earnings at $0.00 EPS, Q3 2027 earnings at $0.01 EPS and Q4 2027 earnings at ($0.01) EPS.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.03). Cytosorbents had a negative return on equity of 309.53% and a negative net margin of 48.94%.The firm had revenue of $9.63 million for the quarter, compared to analysts’ expectations of $9.38 million.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytosorbents in a report on Monday, July 6th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Cytosorbents currently has an average rating of “Hold” and a consensus price target of $5.38.

Cytosorbents Trading Down 0.6%

Shares of CTSO stock opened at $0.36 on Monday. The stock’s fifty day moving average is $0.40 and its two-hundred day moving average is $0.55. The company has a debt-to-equity ratio of 4.70, a quick ratio of 0.81 and a current ratio of 1.09. The firm has a market capitalization of $22.62 million, a P/E ratio of -1.24 and a beta of 1.39. Cytosorbents has a fifty-two week low of $0.35 and a fifty-two week high of $1.19.

Hedge Funds Weigh In On Cytosorbents

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CTSO. Citadel Advisors LLC grew its holdings in Cytosorbents by 127.3% in the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after buying an additional 36,790 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Cytosorbents by 149.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after acquiring an additional 37,519 shares during the period. CIBC Bancorp USA Inc. purchased a new position in shares of Cytosorbents during the 3rd quarter worth $161,000. CM Management LLC boosted its position in shares of Cytosorbents by 14.6% during the 4th quarter. CM Management LLC now owns 1,476,500 shares of the medical research company’s stock valued at $944,000 after acquiring an additional 188,372 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Cytosorbents by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after acquiring an additional 79,535 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

Insider Buying and Selling at Cytosorbents

In related news, CEO Phillip P. Chan purchased 251,136 shares of the company’s stock in a transaction dated Friday, June 12th. The stock was acquired at an average cost of $0.40 per share, for a total transaction of $100,454.40. Following the completion of the transaction, the chief executive officer directly owned 1,734,099 shares of the company’s stock, valued at approximately $693,639.60. This trade represents a 16.93% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 7.80% of the stock is currently owned by corporate insiders.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.